Reform to federal cannabis laws continues to move in a positive direction. It’s just about impossible to miss as the data – and the subsequent opportunities – stacking up.
There are 33 U.S. states and the District of Columbia offering some level of legalization following the 2018 midterm elections.
Agencies like the U.S. Food and Drug Administration are fast-tracking cannabis-based pharmaceutical research and testing, even approving one product (Epidiolex by GW Pharmaceuticals) that has since been rescheduled by the U.S. Drug Enforcement Administration. It’s now a Schedule 5 drug, alongside of Robitussin AC, instead of on Schedule 1, which includes heroin.